Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma

Official record

Identifier

NCT07726329

Recruiting locations

country

Taiwan

Interventions studied

dendritic cells

Lead sponsor

Chang Gung Memorial Hospital

Target enrolment

100 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Active, not recruiting

First posted

Jul 24, 2026

Last updated on the registry

Jul 24, 2026

Age

18 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* advanced HCC patients, no response to standard treatment; WBC : 3000-12000/ul; platelet: \>80000/ul; anticipated survival \> 3 months, measurable tumors.

Exclusion Criteria:

* HIV; BCLC stage; acute infection; sepsis; other advanced malignancy; acute liver failure;